Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886287 | 1.00 | KMT2A (0.38) | KMT2ATSHRMEN1LMNAHPGD | |
| SCHEMBL4891017 | 1.00 | KMT2A (0.38) | KMT2ATSHRMEN1LMNAHPGD | |
| SCHEMBL5328234 | 0.97 | KMT2A (0.36) | KMT2ATSHRMEN1LMNAHPGD | |
| SCHEMBL4892722 | 0.95 | HRH3 (0.34) | KMT2ATSHRMEN1LMNAHPGD | |
| SCHEMBL4891902 | 0.95 | HRH3 (0.34) | KMT2ATSHRMEN1LMNAHPGD | |
| SCHEMBL4891898 | 0.95 | HRH3 (0.34) | KMT2ATSHRMEN1LMNAHPGD | |
| SCHEMBL4883292 | 0.91 | F2 (0.36) | KMT2AMEN1LMNAHPGDALDH1A1 | |
| SCHEMBL4893645 | 0.91 | F2 (0.36) | KMT2AMEN1LMNAHPGDALDH1A1 | |
| SCHEMBL4885059 | 0.91 | F2 (0.36) | KMT2AMEN1LMNAHPGDALDH1A1 | |
| SCHEMBL4893430 | 0.89 | F2 (0.34) | KMT2ATSHRLMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221063-A1 | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | claimed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| WO-2007008142-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-20080221063-A1 | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2007008143-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008142-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008146-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221063-A1 | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa | F12, F11, C1R | KMT2A 2425/4885TSHR 384/4885MEN1 1358/4885 |
| US-20080200431-A1 | 6-{4-[4-(3-Chloro-1H-indole-6-sulfonyl)-3-hydroxy-piperazine-1-carbonyl]-piperidin-1-yl}-2-methyl-2H-pyridazin-3-one for example; antithrombotic and anticoagulant; synthesis; combination therapy | CYC1, F2, CBR1 | KMT2A 2842/4885TSHR 188/4885MEN1 2133/4885 |
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | KMT2A 4074/4885TSHR 193/4885MEN1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.